Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042033 | 0.86 | MAPT (0.47) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL4167217 | 0.86 | GPR3 (0.35) | GPR3 | |
| SCHEMBL19257713 | 0.82 | GPR3 (0.56) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL3058488 | 0.81 | GPR3 (0.48) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL508145 | 0.81 | GPR3 (0.54) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL23056950 | 0.80 | GPR3 (0.48) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL21369776 | 0.78 | GPR3 (0.50) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL5798057 | 0.78 | GPR3 (0.50) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL176274 | 0.77 | GPR3 (0.48) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL5460623 | 0.75 | GPR3 (0.47) | GPR3MAPTALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054470-B2 | Photoswitchable dibenzothienylmethyl triphenylphosphonium derivatives and methods of treating cancer therewith | SAINT LOUIS UNIVERSITY (US) | 2024-08-06 | — | — | US | disclosed |
| US-20210147378-A1 | PHOTOSWITCHABLE DIBENZOTHIENYLMETHYL TRIPHENYLPHOSPHONIUM DERIVATIVES AND METHODS OF TREATING CANCER THEREWITH | SAINT LOUIS UNIVERSITY (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2019199911-A1 | PHOTOSWITCHABLE DIBENZOTHIENYLMETHYL TRIPHENYLPHOSPHONIUM DERIVATIVES AND METHODS OF TREATING CANCER THEREWITH | SAINT LOUIS UNIVERSITY (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054470-B2 | Photoswitchable dibenzothienylmethyl triphenylphosphonium derivatives and methods of treating cancer therewith | RB1, NTPCR, DPYD | GPR3 4503/4885MAPT 4208/4885ALDH1A1 177/4885 |
| US-20210147378-A1 | PHOTOSWITCHABLE DIBENZOTHIENYLMETHYL TRIPHENYLPHOSPHONIUM DERIVATIVES AND METHODS OF TREATING CANCER THEREWITH | RB1, NTPCR, DPYD | GPR3 4503/4885MAPT 4208/4885ALDH1A1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.